The Committee on Publication Ethics (COPE), of which PLoS Medicine, and other PLoS journals, are members, has recently released guidance for editors on the thorny topic of “research, audit and service evaluations”. This guidance aims to help editors decide how to handle their journal’s requirement for ethical review in relation to these types of studies. As outlined by COPE, most journals require that for any research involving human subjects, the study has been approved by a properly constituted ethics committee.
Archives for July 2008
We're seeking more articles in the field of Natural and Synthetic Vision (an area in which we have already published 40+ papers, you can see them listed below). At the current time we are especially interested in articles that will be of interest to those who are implementing Synthetic Vision Systems.
We would like to expand our coverage of this area by announcing the publication of a Special Collection that emphasizes electronic and computational image processing, including machine learning in vision. We look forward to publishing your research.
Panellists noted that the recent NIH public access policy emphasises free not open access. That is, the policy may lead to freely accessible publications (for which publishers or organisations may reap profits from charging authors a fee to deposit their manuscripts), but these will remain under restrictive licenses (thus limiting text-mining).
Just spotted an interesting letter in last week’s Lancet discussing selective reporting of clinical trials. This may sound like something you’ve heard many times before (eg here) but in the Lancet letter the authors describe what happenned to trials for which the original protocols were posted on Lancet’s own website.
The FDA’s recent proposal to allow drug companies to send doctors journal articles about off-label drug use has come under major fire over the last few months.
Last night, we upgraded the journal websites to Topaz 0.9 rc1 (rc1 because this is a “beta” 0.9 release). The development for this release focused on performance and stability – specifically to alleviate the sluggish speed of the websites and the pain of ingests.
The US presidential campaign, while fascinating, tends to overshadow policy debates in other countries.
This week the debate about safe-injection sites in Canada again reared its ugly head. Safe-injection sites, which exist in only a few cities in the world, are health facilities that allow injection drug users to legally use under supervision, with the aim of reducing harm to users’ health and to the public.
When we launched PLoS Medicine in October 2004, the editors announced that we would “not to be part of the cycle of dependency that has formed between journals and the pharmaceutical industry.”